{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.3, Schedule of Activities', 'Updated SoA footnote \"d\" for clarity', 'Add language for clarity', 'Section 7.1.2, Liver Chemistry', 'Removed algorithm and added', 'Correction of editing errors', 'Stopping Criteria', 'verbiage to clarify when discontinuation', 'inadvertently left in the', 'of study intervention is required', 'previous protocol version', 'Add language for clarity', 'Section 8.10.1, HIV-1 Exploratory', 'Clarified language around use of', 'Add language for clarity', 'Analysis', 'samples for additional testing', 'Section 11.9 Appendix 9: Liver', 'Clarified language for required actions', 'Add language for clarity', 'Safety: Required Actions and', 'and follow-up for liver events', 'Follow-up Assessments and Study', 'Intervention Restart Guidelines', 'Section 11.9.1, Liver Chemistry', 'Removed duplicate criteria from table', 'Correction of editing errors', 'Stopping Criteria: Required', 'inadvertently left in the', 'Actions and Follow up', 'previous protocol version', 'Assessments', 'Section 11.9.2, Study Intervention', 'Updated Section title', 'Correction of editing errors', 'Restart after Stopping for Liver', 'Clarified language for ViiV-specific', 'Add language for clarity', 'Criteria', 'criteria for restart after stopping for a', 'liver event', 'Amendment 03/CHI-1, 31-MAY-2019', 'Overall Rationale for the Country-Specific Amendment: This is a country-specific', 'amendment for administrative purposes applicable only to China. All edits removed those', 'tests which are not able to be conducted in China due to laboratory limitations. These', 'include collection of specific virology specimens for virological testing of linkage and', 'minority species analyses, low level HIV-1 RNA quantitation, viral DNA quantitation,', 'measurement of viral replicative capacity all biomarkers, and those of telomerase', 'function and length. Additionally, in the event of any liver stopping events, the', 'requirements for serum acetaminophen, and blood samples for pharmacokinetic (PK)', 'analysis were deleted for the same reason.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 8.8, Biomarkers', 'Removed all biomarkers', 'Will not be conducted in', 'subjects at study sites in', 'China. Remaining', 'analytes/tests are', 'medically necessary', 'Section 8.10, HIV-1 Polymerase', 'Revised description of specific', 'Will not be conducted in', 'Viral Genotyping and Phenotyping', 'virology specimens and tests', 'subjects at study sites in', 'performed.', 'China. Those tests which', 'remain are medically', 'necessary and not for', 'exploratory purposes.', 'Section 8.10.1, HIV-1 Exploratory', 'Section deleted.', 'Will not be conducted in', 'Analysis', 'subjects at study sites in', 'China. Those tests which', 'remain are medically', '168']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'necessary and not for', 'exploratory purposes.', 'Section 1.3, Schedule of Activities', 'Deleted SoA list of tests and the', 'Revised to reflect only', '(SoA)', 'accompanying footnotes', 'those tests to be', 'bb,cc,dd,ee.and ff and updated order', 'conducted in subjects at', 'of footnotes accordingly', 'study sites in China', 'Section 3. Objectives and', 'Deleted phenotypic resistance;', 'Revised for clarity', 'Endpoints', 'Exploratory section title revised to', 'Tertiary. Revised row two objectives', 'and endpoints and deleted row three', 'information', 'Section 7.1.1.2., Managing', 'Deleted phenotype/phenotypic from', 'Revised for clarity.', 'Participants Meeting Precautionary', 'section', 'Virologic Withdrawal (PVW) or', 'Confirmed Virologic Withdrawal', '(CVW) Criteria', 'Section 8.1 Efficacy Assessments', 'Clarified HIV RNA quantification', 'Revised for clarity', 'methods. Deleted text referring to', 'exploratory analyses', 'Section 8.4, Treatment of Overdose', 'Removed text regarding plasma sample', 'Will not be conducted in', 'for PK analysis', 'subjects at study sites in', 'China.', 'Section 8.5, Pharmacokinetics,', 'Statements regarding plasma sample', 'Will not be conducted in', 'subsections Liver Event and', 'for PK analysis were deleted', 'subjects at study sites in', 'Overdose', 'China', 'Section 9.4.1. Efficacy Analyses', 'Removed text referring to exploratory', 'Revised for clarity', 'and Section 9.4.2. Safety Analyses', 'analyses', 'Section 11.2.2., Sub-study', 'Subtitle for Table revised to Tertiary,', 'Revised for clarity', 'Objectives and Endpoints', 'as this information from this substudy', 'is of medical importance', 'Section 11.7 Appendix 7: Clinical', 'Revised table contents and footnotes', 'Revised to reflect only', 'Laboratory Tests, Table 5, Protocol', 'those tests to be', 'Required Safety Laboratory', 'conducted in subjects at', 'Assessments', 'study sites in China .', 'Section 11.9.1, Liver Chemistry', 'Removed text and accompanying', 'Will not be conducted in', 'Stopping Criteria: Required Actions', 'footnote regarding serum', 'subjects at study sites in', 'and Follow up Assessments', 'acetaminophen and blood sample for', 'China', 'pharmacokinetic analysis', 'Section 11.13, Country specific', 'The rationale for making this', 'All laboratory tests are', 'requirements', 'amendment is provided.', 'required to be conducted', 'within country.', 'Section 11.14, Protocol', 'All prior protocol amendments are', 'Standard practice to list', 'amendment history', 'listed.', 'prior protocol', 'amendments', '169']\n\n###\n\n", "completion": "END"}